Inhibikase Therapeutics, Inc.
Business
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing IKT-001, a prodrug of imatinib, for pulmonary arterial hypertension (PAH), a rare progressive pulmonary vascular disease. The company is advancing IKT-001 through a Phase 3 adaptive clinical trial (IMPROVE-PAH) designed to evaluate efficacy, safety and tolerability in PAH patients. Inhibikase holds global commercialization rights to IKT-001 with U.S. patent protection through 2039, and separately licenses risvodetinib to ABLi Therapeutics.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 30 | 17 | 14 | 12 | 11 | |
| Selling, general and administrative | 24 | 11 | 7 | 6 | 7 | |
| Change in fair value contingent consideration | −1 | 0 | — | — | — | |
| Total costs and expenses | 52 | 29 | 20 | 18 | 18 | |
| Loss from operations | −52 | −29 | −20 | −18 | −15 | |
| Interest income | 4 | 1 | 1 | 74,453 | −19,923 | |
| Net loss | −48 | −28 | −19 | −18 | −15 | |
| Unrealized gain (loss) on marketable securities | 59,050 | −38,125 | −103,841 | 104,718 | 0 | |
| Comprehensive loss | −48 | −28 | −19 | −18 | −15 | |
| Net loss per share - basic | −0.49 | −1.16 | −3.16 | −4.28 | −0.81 | |
| Net loss per share - diluted | −0.49 | −1.16 | −3.16 | −4.28 | −0.81 | |
| Weighted-average number of shares_basic | 98 | 24 | 6 | 4 | 18 | |
| Weighted-average number of shares_diluted | 98 | 24 | 6 | 4 | 18 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 139 | 56 | 9 | 7 | 41 | |
| Marketable securities | 40 | 41 | 4 | 16 | 0 | |
| Prepaid research and development | 1 | 81,308 | 219,817 | 1 | 107,000 | |
| Prepaid expenses and other current assets | 343,374 | 826,473 | 739,179 | 163,452 | 2 | |
| Total current assets | 180 | 98 | 14 | 24 | 42 | |
| Equipment and improvements, net | 0 | 47,100 | 73,372 | 236,532 | 0 | |
| Right-of-use asset | 0 | 101,437 | 222,227 | 328,643 | 0 | |
| Prepaid research and development, noncurrent | 1 | 0 | — | — | — | |
| Amount held as a retainer | 95,121 | 0 | — | — | — | |
| Total assets | 181 | 99 | 15 | 25 | 42 | |
| Accounts payable | 1 | 943,019 | 646,767 | 1 | 1 | |
| Lease obligation, current | 0 | 110,517 | 150,095 | 145,836 | 0 | |
| Accrued expenses and other current liabilities | 4 | 3 | 2 | 2 | 3 | |
| Contingent consideration liability | 3 | 0 | — | — | — | |
| Total current liabilities | 8 | 4 | 3 | 4 | 4 | |
| Total liabilities | 8 | 4 | 4 | 4 | 4 | |
| Commitments and contingencies (see Note 15) | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2025 and December 31, 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value; 500,000,000 and 100,000,000 shares authorized; 131,691,237 and 69,362,439 shares issued and outstanding (including 4,149,252 and 0 contingently issuable shares - see Note 7) at December 31, 2025 and December 31, 2024, respectively | 131,691 | 69,362 | 6,186 | 4,224 | 25,155 | |
| Additional paid-in capital | 315 | 189 | 78 | 69 | 68 | |
| Accumulated other comprehensive income (loss) | 21,802 | −37,248 | 877 | 104,718 | 0 | |
| Accumulated deficit | −143 | −94 | −67 | −48 | −30 | |
| Total stockholders' equity | 173 | 95 | 11 | 21 | 38 | |
| Total liabilities and stockholders' equity | 181 | 99 | 15 | 25 | 42 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 60,499 | 26,272 | 177,398 | 6,723 | 0 | |
| Stock-based compensation expense | 15 | 8 | 500,148 | 458,147 | 2 | |
| Write-off of in-process research and development | 7 | 0 | — | — | — | |
| Non-cash accretion on marketable securities | −936,975 | 0 | — | — | — | |
| Operating lease right of use assets | 101,437 | 120,790 | 106,416 | 38,055 | — | |
| Prepaid expenses and other assets | 532,732 | −616,523 | −55,387 | 1 | −1 | |
| Prepaid research and development | −2 | 138,508 | 897,803 | −1 | 667,356 | |
| Other assets | −95,121 | 0 | — | — | — | |
| Accounts payable | 146,827 | 271,782 | −504,406 | 61,395 | −630,902 | |
| Operating lease liabilities | −110,517 | −129,702 | −111,068 | −9,859 | — | |
| Accrued expenses and other current liabilities | 1 | 420,075 | −138,481 | −317,324 | 2 | |
| Net cash used in operating activities | −28 | −19 | −18 | −17 | −14 | |
| Purchases of equipment and improvements | −13,399 | 0 | −14,238 | −243,255 | 0 | |
| Purchases of investments - marketable securities | −39 | −60 | −29 | −21 | 0 | |
| Maturities of investments - marketable securities | 42 | 23 | 41 | 5 | 0 | |
| Acquired in-process research and development | −438,624 | 0 | — | — | — | |
| Net cash provided by (used in) investing activities | 2 | −37 | 12 | −16 | 0 | |
| Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 108 | 103 | 9 | 0 | 0 | |
| Issuance of common stock from exercise of stock options | 845,468 | 0 | 0 | 44,142 | 78,500 | |
| Net cash provided by financing activities | 108 | 103 | 8 | −204,769 | 41 | |
| Net increase in cash and cash equivalents | 83 | 47 | 2 | −34 | 27 | |
| Issuance costs | 7 | 11 | 1 | — | — | |
| Contingent consideration | 4 | 0 | — | — | — | |
| Non-cash IPR&D acquired through common stock contingently issued shares | 2 | 0 | — | — | — | |
| Non-cash financing costs included in Accounts payable | 373,231 | 0 | — | — | — | |
| CorHepta transaction costs | 175,000 | 0 | — | — | — | |
| Write-off of fully depreciated equipment and improvements | 117,224 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Inhibikase Therapeutics, Inc.'s CIK number?
Inhibikase Therapeutics, Inc.'s SEC CIK number is 0001750149 (1750149). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Inhibikase Therapeutics, Inc.'s SEC filings?
All of Inhibikase Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Inhibikase Therapeutics, Inc. last report earnings?
Inhibikase Therapeutics, Inc. (IKT) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219610). This is Inhibikase Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Inhibikase Therapeutics, Inc.'s most recent earnings 8-K?
Inhibikase Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219610. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Inhibikase Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →